214 related articles for article (PubMed ID: 33765337)
21. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
[TBL] [Abstract][Full Text] [Related]
22. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
23. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
25. Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma.
Bimbatti D; Ciccarese C; Fantinel E; Sava T; Massari F; Bisogno I; Romano M; Porcaro A; Brunelli M; Martignoni G; Mazzarotto R; Artibani W; Tortora G; Iacovelli R
Urol Oncol; 2018 Dec; 36(12):526.e13-526.e18. PubMed ID: 30301699
[TBL] [Abstract][Full Text] [Related]
26. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
[TBL] [Abstract][Full Text] [Related]
27. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
[TBL] [Abstract][Full Text] [Related]
28. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
Reig Torras O; Mishra A; Christie A; McKenzie T; Onabolu O; Singla N; Plimack ER; Suárez C; Ornstein MC; Alpaugh RK; Elias R; Bowman IA; McKay RM; Przybycin C; Kapur P; Brugarolas J; Rini B
Eur Urol; 2022 Jun; 81(6):555-558. PubMed ID: 34980496
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
Molina AM; Lin X; Korytowsky B; Matczak E; Lechuga MJ; Wiltshire R; Motzer RJ
Eur J Cancer; 2014 Jan; 50(2):351-8. PubMed ID: 24051327
[TBL] [Abstract][Full Text] [Related]
30. Active surveillance for metastatic or recurrent renal cell carcinoma.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; Jeong IG; Song C; Hong B; Hong JH; Ahn H
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1421-8. PubMed ID: 24752340
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
[TBL] [Abstract][Full Text] [Related]
32. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
33. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
Kim MS; Chung HS; Hwang EC; Jung SI; Kwon DD; Hwang JE; Bae WK; Park JY; Jeong CW; Kwak C; Song C; Seo SI; Byun SS; Hong SH; Chung J
J Korean Med Sci; 2018 Dec; 33(51):e325. PubMed ID: 30546281
[TBL] [Abstract][Full Text] [Related]
35. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Pal S; Gong J; Mhatre SK; Lin SW; Surinach A; Ogale S; Vohra R; Wallen H; George D
BMC Cancer; 2019 Jun; 19(1):548. PubMed ID: 31174493
[TBL] [Abstract][Full Text] [Related]
36. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
37. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
[TBL] [Abstract][Full Text] [Related]
38. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
39. Comparative Analysis of Surgery, Thermal Ablation, and Active Surveillance for Renal Oncocytic Neoplasms.
Miller BL; Mankowski Gettle L; Van Roo JR; Ziemlewicz TJ; Best SL; Wells SA; Lubner MG; Hinshaw JL; Lee FT; Nakada SY; Huang W; Abel EJ
Urology; 2018 Feb; 112():92-97. PubMed ID: 29030073
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
